上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2025 年第二次临时股东会的 上海市锦天城律师事务所 法律意见书 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2025 年第二次临时股东会的 法律意见书 致：浙江京新药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江京新药业股份有限公 司（以下简称"公司"或"京新药业"）委托，就公司召开 2025 年第二次临时股东 会（以下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称《公司法》）、《上市公司股东会规则》等法律、法规、规章和其他规范性 文件以及《浙江京新药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚 ...

Group 1 - The company, Jingxin Pharmaceutical (002020), stated on October 17 that it will disclose the number of shareholders at the end of the reporting period in its regular reports [1] - For non-regular reports, shareholders can provide proof of shareholding to the company's secretary office, which will verify and provide the information [1]

Core Viewpoint - The company emphasizes its commitment to improving operational performance while also focusing on market value management to enhance shareholder returns [1] Group 1 - The company is dedicated to achieving better operational results [1] - The company aims to effectively manage its market value [1] - The company seeks to provide returns to all shareholders [1]

上海锦天城（杭州）律师事务所 关于浙江京新药业股份有限公司 第四期员工持股计划的 法律意见书 地址：杭州市上城区富春路 308 号华成国际发展大厦 11/12 层 电话：（86571）8983-8088 传真：（86571）8983-8099 邮编：310020 上海锦天城（杭州）律师事务所 法律意见书 上海锦天城（杭州）律师事务所 关于浙江京新药业股份有限公司 第四期员工持股计划的 法律意见书 致：浙江京新药业股份有限公司 上海锦天城（杭州）律师事务所（以下简称"本所"）接受浙江京新药业股 份有限公司（以下简称"京新药业"或"公司"）的委托，担任公司第四期员工 持股计划（以下简称"本次员工持股计划"）的法律顾问，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《关于上市公司实施员工持股计划试点的指导意见》（以 下简称"《指导意见》"）、《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》（以下简称"《自律监管指引》"）、《上市公司股 权激励管理办法》（以下简称"《管理办法》"）等有关法律法规的规定，按照 律师行业公认的业务 ...

Core Viewpoint - Jingxin Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 51.26% but a recent decline in the last five and twenty trading days [1][2]. Financial Performance - For the first half of 2025, Jingxin Pharmaceutical reported revenue of 2.017 billion yuan, a year-on-year decrease of 6.20%, and a net profit attributable to shareholders of 388 million yuan, down 3.54% [2]. - The company has distributed a total of 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed over the past three years [3]. Stock Market Activity - As of October 14, the stock price was 18.86 yuan per share, with a market capitalization of 16.239 billion yuan. The trading volume was 111 million yuan, with a turnover rate of 0.80% [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) once this year, with a net buy of 111 million yuan on July 4 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 25,700, a slight decrease of 0.11%, with an average of 28,196 circulating shares per shareholder, an increase of 0.11% [2]. - The fifth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 9.6492 million shares, a decrease of 15.3917 million shares from the previous period [3].

Core Viewpoint - Jingxin Pharmaceutical (002020) is committed to improving its operational management to achieve better performance and return value to all shareholders [1] Group 1 - The company is actively engaging with investors through platforms to address their inquiries [1] - The management emphasizes the importance of operational efficiency in driving future growth [1]

Core Viewpoint - Jingxin Pharmaceutical's stock price has experienced fluctuations, with a year-to-date increase of 54.30% but a recent decline in the last five and twenty trading days [1][2]. Financial Performance - For the first half of 2025, Jingxin Pharmaceutical reported revenue of 2.017 billion yuan, a year-on-year decrease of 6.20%, and a net profit attributable to shareholders of 388 million yuan, down 3.54% year-on-year [2]. - The company has cumulatively distributed 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed over the past three years [3]. Stock Market Activity - As of October 13, the stock price was 19.24 yuan per share, with a market capitalization of 16.566 billion yuan. The trading volume was 156 million yuan, with a turnover rate of 1.11% [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of 111 million yuan on July 4 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 25,700, a decrease of 0.11% from the previous period, with an average of 28,196 circulating shares per shareholder, an increase of 0.11% [2]. - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 9.6492 million shares, a decrease of 15.3917 million shares from the previous period [3].

Core Viewpoint - The company has submitted a listing application for its new drug, hydrochloride cariprazine, and is preparing for its commercialization in the domestic market [1] Group 1 - The company is the only manufacturer and seller of hydrochloride cariprazine in the market for at least the next 3 to 5 years [1] - The existing sales team has experience in selling drugs in the mental and neurological fields, which is expected to facilitate the commercialization of hydrochloride cariprazine [1] - The company aims to achieve good sales performance for hydrochloride cariprazine following its market entry [1]

Core Points - On October 10, 2025, the company will hold its eighth employee representative assembly, where the election of Xu Xiaojun as the employee representative director for the ninth board of directors will take place [2] Summary by Category - **Company Announcement** - The company announced the date for its eighth employee representative assembly, scheduled for October 10, 2025 [2] - The assembly will involve the election of Xu Xiaojun as the employee representative director [2]

证券代码：002020 证券简称：京新药业 公告编号：2025054 浙江京新药业股份有限公司董事会 2025 年 10 月 11 日 职工代表董事简介 浙江京新药业股份有限公司（以下简称"公司"）第八届董事会任期即将届 满，公司根据《公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章程》等法律法 规、规范性文件的有关规定，开展董事会换届选举工作。 公司于 2025 年 10 月 10 日召开第八届三次职工（会员）代表大会，经与会 职工代表审议，同意选举徐小军先生为公司第九届董事会职工代表董事（简历详 见附件）。徐小军先生将与公司 2025 年第一次临时股东大会选举产生的第九届 董事会非独立董事和独立董事共同组成第九届董事会，任期三年，与第九届董事 会任期一致。 第九届董事会职工代表董事徐小军先生符合《公司法》《公司章程》等法律 法规、规范性文件关于董事任职的资格和条件。本次换届选举完成后，第九届董 事会中兼任公司高级管理人员以及由职工代表担任的董事人数总计未超过公司 董事总数的二分之一，符合相关法律法规的要求。 特此公告。 浙江京新药业股 ...